5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018

  • ID: 4576068
  • Drug Pipelines
  • 50 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AnaMar AB
  • Astellas Pharma Inc
  • RaQualia Pharma Inc
  • MORE
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018

Summary:

According to the recently published report '5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2018'; 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - 5-Hydroxytryptamine receptor 2B (5-HT2B) or serotonin receptor 2B is a protein encoded by the HTR2B gene. It plays a role in the regulation of behavior, including impulsive behavior. It protects cardiomyocytes against apoptosis. It plays a role in the adaptation of pulmonary arteries to chronic hypoxia and vasoconstriction.

The report '5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2018' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Immunology, Respiratory, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Ophthalmology which include indications Drug Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Idiopathic Pulmonary Fibrosis, Psychosis, Pulmonary Arterial Hypertension, Schizophrenia, Systemic Sclerosis (Scleroderma), Alzheimer's Disease, Autism, Binge Eating Disorder, Bipolar Disorder (Manic Depression), Cirrhosis, Diarrhea, Fibrosis, Insomnia, Irritable Bowel Syndrome, Liver Fibrosis, Major Depressive Disorder, Migraine, Neuroendocrine Tumors, Non-Alcoholic Steatohepatitis (NASH), Obesity, Obsessive-Compulsive Disorder, Ocular Hypertension, Open-Angle Glaucoma, Psychiatric Disorders, Psychological Disorders, Schizoaffective Disorder and Sedation.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
  • The report reviews 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AnaMar AB
  • Astellas Pharma Inc
  • RaQualia Pharma Inc
  • MORE
Introduction

Report Coverage

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Overview

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Companies Involved in Therapeutics Development

AnaMar AB

Astellas Pharma Inc

Neurim Pharmaceuticals Ltd

RaQualia Pharma Inc

Reviva Pharmaceuticals Inc

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Drug Profiles

AM-1476 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DDD-024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-240 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00310941 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SERx-480 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize HTR2B for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terguride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Dormant Products

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Discontinued Products

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Product Development Milestones

Featured News & Press Releases

Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension

Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease

Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)

Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease

May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016

Apr 20, 2016: RaQualia Receives a Patent Allowance for 5-HT 2B Antagonist in Korea

Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits

Jun 01, 2015: RaQualia to Initiate Phase I Clinical Trial for 5-HT2B Antagonist in UK

Aug 20, 2014: RaQualia Receives a Patent Allowance for 5-HT2B Antagonist in Japan

Nov 05, 2013: Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for RP5063

Jul 11, 2013: Novel antipsychotic shows early promise

Apr 09, 2013: Reviva Pharma Reports Positive Top-Line Results From Phase II Study Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder

Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia

Jan 14, 2013: Reviva Pharma Completes Patient Enrollment In Phase II Trial Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AnaMar AB, H1 2018

Pipeline by Astellas Pharma Inc, H1 2018

Pipeline by Neurim Pharmaceuticals Ltd, H1 2018

Pipeline by RaQualia Pharma Inc, H1 2018

Pipeline by Reviva Pharmaceuticals Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AnaMar AB
  • Astellas Pharma Inc
  • Neurim Pharmaceuticals Ltd
  • RaQualia Pharma Inc
  • Reviva Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll